Ultragenyx Pharmaceutical
RARE
126 hedge funds and large institutions have $1.96B invested in Ultragenyx Pharmaceutical in 2015 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 54 increasing their positions, 25 reducing their positions, and 10 closing their positions.
260% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 10
116% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 25
60% more capital invested
Capital invested by funds: $1.23B → $1.96B (+$734M)
32% more call options, than puts
Call options by funds: $3.73M | Put options by funds: $2.83M
26% more funds holding
Funds holding: 100 → 126 (+26)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$50.8M |
| 2 |
Millennium Management
New York
|
+$37.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.6M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$20.4M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$28.7M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$27.8M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$12.1M |
| 4 |
CI
Cowen Inc
New York
|
-$8.08M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $345 | +$25.9K | +467 | +9% |
|
|
LCP
127
Lamond Capital Partners
San Francisco,
California
| – | -$3.42M | -77,940 | Closed |
|
|
NI
128
Numeric Investors
Boston,
Massachusetts
| – | -$2.47M | -56,382 | Closed |
|
|
MSA
129
Mason Street Advisors
Milwaukee,
Wisconsin
| – | -$1.96M | -44,630 | Closed |
|
|
TC
130
TFS Capital
West Chester,
Pennsylvania
| – | -$1.09M | -24,889 | Closed |
|
|
TI
131
Trexquant Investment
Stamford,
Connecticut
| – | -$675K | -15,400 | Closed |
|
|
SCA
132
Secor Capital Advisors
New York
| – | -$507K | -11,564 | Closed |
|
|
MLICM
133
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$252K | -5,748 | Closed |
|
134
Group One Trading
Chicago,
Illinois
| – | -$39.8K | -716 | Closed |
|
|
PMAM
135
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$13K | -300 | Closed |
|
|
BRWA
136
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$1 | -19 | Closed |
|
RARE Hedge Fund Activity: Q1 2015 in Review
126 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2015, worth a combined $1.96B — up 60% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RARE positions and 10 closed out — a net gain of 26 holders — while 54 added to existing stakes and 25 trimmed.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $50.8M. The largest seller was Fidelity International, cutting an estimated $28.7M.
- 126 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2015, up from 100 in Q4 2014.
- Funds reported $1.96B of Ultragenyx Pharmaceutical stock for Q1 2015, up 60% quarter-over-quarter.
- 36 funds opened new Ultragenyx Pharmaceutical positions in Q1 2015 and 10 closed out, a net change of +26 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2015 was Columbia Wanger Asset Management, an estimated $50.8M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2015 was Fidelity International, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2015.